Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

________________________

 

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

June 20, 2019
Date of Report (Date of earliest event reported)

 

AEVI GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)

 

Delaware	1-35112	98-0217544
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

 

435 Devon Park Drive, Suite 715

Wayne, Pennsylvania 19087

(Address of principal executive offices, zip code)

 

[phone]
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common stock, par value $0.0001 per share	GNMX	Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

 

On June 20, 2019, Aevi Genomic Medicine, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:

 

Proposal 1: Election of seven directors to hold office until the 2020 Annual Meeting of Stockholders.

 

 

Nominee		For		Against		Abstentions		Broker Non-Votes
Sol J. Barer		31,514,669		1,525,659		24,786		18,616,186
Eugene A. Bauer		31,478,816		1,558,812		27,486		18,616,186
Matthew D. Bayley		31,501,488		1,530,547		33,079		18,616,186
Alastair Clemow		31,516,368		1,518,527		30,219		18,616,186
Michael F. Cola		31,516,970		1,520,654		27,490		18,616,186
Barbara G. Duncan		28,236,248		4,797,825		31,041		18,616,186
Joseph J. Grano		31,493,864		1,543,764		27,486		18,616,186

 

  Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the current fiscal year ending December 31, 2019.

 

For		Against		Abstained
50,912,726		667,317		101,257

 

  Proposal 3: Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers.

 

For		Against		Abstentions		Broker Non-Votes
31,274,263		1,703,403		87,448		18,616,186

  

Proposal 4: Indication, on a non-binding, advisory basis, of the preferred frequency of further executive compensation advisory votes.

 

Every 1 Year		Every 2 Years		Every 3 Years		Abstentions		Broker Non-Votes
28,101,842		225,879		4,683,758		53,635		18,616,186

  

 

SIGNATURES

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	AEVI GENOMIC MEDICINE, INC.
	By:	/s/ Michael F. Cola
		Name: Michael F. Cola
		Title: President and Chief Executive Officer

Date: June 24, 2019